You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR NARATRIPTAN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NARATRIPTAN HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00282165 ↗ Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated FPC De Kijvelanden, Poortugaal Phase 4 2006-11-01 In a double blind randomized clinical trial with cross-over design, treatment using naratriptan will be compared to placebo within a group of 30 convicts with psychiatric disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that addition of naratriptan to the individual treatment regime reduces aggression -and improves general outcome- as compared to addition of placebo and is well tolerated in this group and under these conditions.
NCT00282165 ↗ Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated UMC Utrecht Phase 4 2006-11-01 In a double blind randomized clinical trial with cross-over design, treatment using naratriptan will be compared to placebo within a group of 30 convicts with psychiatric disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that addition of naratriptan to the individual treatment regime reduces aggression -and improves general outcome- as compared to addition of placebo and is well tolerated in this group and under these conditions.
NCT00487578 ↗ Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Terminated Clinvest Phase 4 2006-10-01 The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.
NCT00487578 ↗ Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Terminated GlaxoSmithKline Phase 4 2006-10-01 The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.
NCT00487578 ↗ Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Terminated Cady, Roger, M.D. Phase 4 2006-10-01 The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.
NCT01059604 ↗ Sumatriptan and Naratriptan Pregnancy Registry Completed GlaxoSmithKline 2001-12-01 Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However, the peak prevalence of migraine is in women of childbearing age. This, coupled with the sporadic nature of migraine attacks and high rates of unplanned pregnancies, makes unintentional exposure to anti-migraine medications during pregnancy likely. Prior to an anti-migraine medication being marketed there are few data available on drug safety in pregnancy: data from animal models may not translate directly to humans and pregnant women are routinely excluded from clinical trials. The Sumatriptan Pregnancy Registry was established by GlaxoSmithKline (GSK) in 1996 to monitor the safety of sumatriptan during pregnancy. It was combined with the Naratriptan Pregnancy Registry in 2001 and data collection on the sumatriptan-naproxen combination (Treximet) began in 2008.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NARATRIPTAN HYDROCHLORIDE

Condition Name

Condition Name for NARATRIPTAN HYDROCHLORIDE
Intervention Trials
Migraine 4
Migraine Disorders 3
Headache 2
Impulse Regulation Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NARATRIPTAN HYDROCHLORIDE
Intervention Trials
Migraine Disorders 6
Headache 3
Cognitive Dysfunction 1
Aggression 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NARATRIPTAN HYDROCHLORIDE

Trials by Country

Trials by Country for NARATRIPTAN HYDROCHLORIDE
Location Trials
United States 5
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NARATRIPTAN HYDROCHLORIDE
Location Trials
Washington 2
Texas 1
North Carolina 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NARATRIPTAN HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for NARATRIPTAN HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NARATRIPTAN HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 5
Withdrawn 2
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NARATRIPTAN HYDROCHLORIDE

Sponsor Name

Sponsor Name for NARATRIPTAN HYDROCHLORIDE
Sponsor Trials
GlaxoSmithKline 4
Roxane Laboratories 2
Ache Laboratorios Farmaceuticos S.A. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NARATRIPTAN HYDROCHLORIDE
Sponsor Trials
Industry 10
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.